Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Companies

Set Alert for Companies

Medtronic Stands To Be Biggest Beneficiary Of J&J's Exit From Insulin Pump Market

Animas, a division of Johnson & Johnson, will stop making Animas Vibe and OneTouch Ping insulin pumps, close operations, and exit the insulin pump business, the company announced Oct. 5. J&J is offering patients currently using these devices the option to transfer to Medtronic device. Medtronic is already the leading supplier of insulin pumps worldwide.

Diabetic Care Companies Commercial
Advertisement

Latest From Companies

Novacyt Raises €9.7M, Ahead Of UK IPO

Clinical diagnostics firm Novacyt has raised €9.7M from UK and French investors ahead of plans to dual list on the London Stock Exchange Alternative Investment Market (AIM). The Cambridge, UK-based company is currently listed on the Euronext Growth Paris exchange.

Diagnostics In Vitro Diagnostics

Medovex Plans US IDE Trial For Its DenerveX Spine Surgery Device

DenerveX is a unique surgical tool used to ablate the nerve and capsular tissue on the posterior surface of the facet joint. preventing the nerve from reattaching with the goal of creating lasting relief from back pain that otherwise might require spinal fusion and/or treatment with opiate drugs.

Companies Innovation

Change At Helm As Tissue Regenix Enters Next Growth Phase

Regenerative medicine firm Tissue Regenix is now seeking a new CEO following the departure of Anthony Odell. The change in leadership comes two months after the company made its maiden M&A deal, acquiring CellRight Technologies.

Regenerative Medicine Companies

genedrive Signs Sysmex To Distribute Decentralized-Setting HCV Test

Molecular diagnostics company genedrive has signed a distribution agreement with Sysmex Corporation to distribute its CE-marked HepC (HCV) ID kit and Genedrive platform in the Europe, Middle East and Africa. The Japanese group is the first commercial partner for genedrive's hepatitis C test for decentralized resource-limited settings.

Commercial Medical Device

Big Promise For TransEnterix Robotic-Surgery Device, But Probably Won't Undermine Intuitive's Market

FDA's recent clearance of TransEnterix's Senhance System signals broad potential for robotically-assisted surgeries but the device is more likely to grow its own space than compete directly with Intuitive Surgical's daVinci products in many cases, analysts suggest.

Approvals Gynecology & Urology

Will AAA's Nuclear Med Offerings Turn M&A Buzz Into A Deal?

Advanced Accelerator Applications (AAA) has hit the headlines with recent rumors of a potential acquisition deal from Novartis. Now that the radiopharmaceutical company has its first therapeutic product approved and ready for commercialization, is AAA really ready to sign the dotted line?

Cancer Companies

OBD's Epigenetic Biomarker Tech Shows Ethnicity Issue-Free Dx Potential

Recent studies completed by epigenetic biomarker company Oxford BioDynamics have shown the company's platform technology EpiSwitch can diagnose and stage breast cancer and Amyotrophic Lateral Sclerosis (ALS). The Oxford spinout is the developer of a blood-based platform test for detecting chromosome confirmation signatures (CCSs), which overcome any ethinicity issues.

Clinical Trials Companies

Philips' Profit To Be Dented By FDA-Decreed AED Sales Halt

On signing a consent decree with the US FDA, Philips is halting manufacture and sales of external defibrillators produced at two facilities until the agency is satisfied the company is complying with current good manufacturing practice requirements. The suspension is expected to impact Philips' EBITA for the fourth quarter 2017 and for 2018.

Cardiology Compliance

MDxHealth Gears Up For Major EU Growth

Cancer diagnostics company MDxHealth is poised for more commercial growth in 2018 following a move to larger lab facilities in Nijmegen, the Netherlands. The move is part of the company's strategy to grow commercialization of its SelectMDx prostate cancer test in Europe and conduct additional R&D activities.

Cancer In Vitro Diagnostics
See All
UsernamePublicRestriction

Register